Safety Evaluation of Multiple CoolSculpting Treatments
The Zeltiq CoolSculpting System
Other Study
Summary
Study start date: March 1, 2013
Actual date on which the first participant was enrolled.The study will evaluate the safety of multiple same-day CoolSculpting treatments and will assess any impact on serum lips or liver-related analytes,
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.35 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Other Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Inclusion Criteria Male or female subjects > 18 years of age. Subject who has been assessed to receive multiple CoolSculpting treatments on the abdomen and flanks, defined as follows: Lower Abdomen - One 60 minute cycle with CoolMax, Right and Left Flank - One 60 minute cycle per flank, with CoolCurve+ or CoolCore, simultaneously. Subject has not had weight change exceeding 10 pounds in the preceding month. Subject with body mass index (BMI) up to 30. BMI is defined as weight in pounds multiplied by 703 divided by the square of the height in inches. Subject agrees to not making any major changes in their diet or lifestyle during the course of the study. Subject has read and signed a written informed consent form. Exclusion Criteria Subject has had an invasive (e.g., liposuction, mesotherapy, abdominoplasty) or non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 6 months. Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month. Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria. Subject has a history of hernia in the area(s) to be treated. Subject is pregnant or intending to become pregnant during the study period (in the next 4 months). Subject is lactating or has been lactating during the past 3 months. Subject is unable or unwilling to comply with the study requirements, such as blood draw. Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device. Subject has a history of lipodosis or other confounding metabolic diseases. Subject is taking or has taken medication within the past 3 months which may affect the metabolic function. Patient has a history of diabetes. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 3 locations
Ed Becker, MD
Walnut Creek, United StatesBowes Dermatology Group
Miami, United States